Base de dados : MEDLINE
Pesquisa : C23.888.821.937.080 [Categoria DeCS]
Referências encontradas : 225 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 23 ir para página                         

  1 / 225 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28061530
[Au] Autor:Ahrari S; Chow R; Goodall S; DeAngelis C
[Ad] Endereço:Department of Pharmacy, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. soha.ahrari@sunnybrook.ca.
[Ti] Título:Anticipatory nausea: current landscape and future directions.
[So] Source:Ann Palliat Med;6(1):1-2, 2017 Jan.
[Is] ISSN:2224-5839
[Cp] País de publicação:China
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Náusea/etiologia
Vômito Precoce/etiologia
[Mh] Termos MeSH secundário: Antieméticos/uso terapêutico
Benzodiazepinas/uso terapêutico
Seres Humanos
Náusea/prevenção & controle
Vômito Precoce/prevenção & controle
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Antiemetics); 0 (Antineoplastic Agents); 12794-10-4 (Benzodiazepines)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170227
[Lr] Data última revisão:
170227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170108
[St] Status:MEDLINE
[do] DOI:10.21037/apm.2016.10.01


  2 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27510314
[Au] Autor:Dupuis LL; Roscoe JA; Olver I; Aapro M; Molassiotis A
[Ad] Endereço:Department of Pharmacy and Research Institute, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada. lee.dupuis@sickkids.ca.
[Ti] Título:2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy.
[So] Source:Support Care Cancer;25(1):317-321, 2017 Jan.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: We aimed to update the 2011 recommendations for the prevention and treatment of anticipatory nausea and vomiting in children and adults receiving chemotherapy. METHODS: The original systematic literature search was updated. Randomized studies were included in the evidence to support this guideline if they as follows: were primary studies published in a journal in full text (i.e., abstracts, letters, book chapters, and dissertations were excluded); published in English; evaluated an intervention for the prevention or treatment of anticipatory nausea and vomiting; reported the proportion of patients experiencing complete control of anticipatory nausea and vomiting consistently and; included at least ten participants per study arm for comparative studies and at least ten participants overall for noncomparative studies. RESULTS: Eighty-eight new citations were identified. Of these, nine were brought to full-text screening; none met inclusion criteria. The guideline panel continues to recommend that anticipatory nausea and vomiting are best prevented through optimization of acute and delayed phase chemotherapy-induced nausea and vomiting control. Benzodiazepines and behavioral therapies, in particular progressive muscle relaxation training, systematic desensitization and hypnosis, continue to be recommended for the treatment of anticipatory nausea and vomiting. CONCLUSIONS: No new information regarding interventions aimed at treating or preventing ANV that met criteria for inclusion in this systematic review was identified. The 2015 MASCC recommendations affirm the content of the 2009 MASCC recommendations for the prevention and treatment of anticipatory nausea and vomiting.
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Antineoplásicos/efeitos adversos
Náusea/induzido quimicamente
Vômito Precoce/induzido quimicamente
Vômito/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/administração & dosagem
Criança
Consenso
Seres Humanos
Quimioterapia de Indução/efeitos adversos
Quimioterapia de Indução/métodos
Guias de Prática Clínica como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160812
[St] Status:MEDLINE


  3 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27048155
[Au] Autor:Parker LA; Limebeer CL; Rock EM; Sticht MA; Ward J; Turvey G; Benchama O; Rajarshi G; Wood JT; Alapafuja SO; Makriyannis A
[Ad] Endereço:Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada. parkerl@uoguelph.ca.
[Ti] Título:A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models.
[So] Source:Psychopharmacology (Berl);233(12):2265-75, 2016 06.
[Is] ISSN:1432-2072
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Drugs that block fatty acid amide hydrolase (FAAH, which elevates anandamide [AEA]) and drugs which block monoacylglycerol (MAGL, which elevates 2-arachidonyl glycerol [2-AG]) have promise in treating both acute and anticipatory nausea in human patients. OBJECTIVE: This study aims to evaluate the relative effectiveness of dual MAGL/FAAH inhibition with either alone to reduce acute and anticipatory nausea in rat models. MATERIALS AND METHODS: AM4302, a new dual MAGL/FAAH inhibitor, was compared with a new selective MAGL inhibitor, AM4301, and new selective FAAH inhibitor, AM4303, for their potential to reduce acute nausea (gaping in taste reactivity) and anticipatory nausea (contextually elicited conditioned gaping) in two rat models. RESULTS: Our in vitro studies indicate that AM4302 blocks human and rat FAAH: IC50 60 and 31 nM, respectively, with comparable potencies against human MAGL (IC50 41 nM) and rat MAGL (IC50 200 nM). AM4301 selectively blocks human and rat MAGL (IC50 8.9 and 36 nM, respectively), while AM4303 selectively inhibits human and rat FAAH (IC50 2 and 1.9 nM), respectively. Our in vivo studies show that the MAGL inhibitor, AM4301, suppressed acute nausea in a CB1-mediated manner, when delivered systemically or into the interoceptive insular cortex. Although the dual FAAH/MAGL inhibitor, AM4302, was equally effective as the FAAH inhibitor or MAGL inhibitor in reducing acute nausea, it was more effective than both in suppressing anticipatory nausea. CONCLUSIONS: Dual FAAH and MAGL inhibition with AM4302 may be an especially effective treatment for the very difficult to treat symptom of anticipatory nausea.
[Mh] Termos MeSH primário: Amidoidrolases/antagonistas & inibidores
Monoacilglicerol Lipases/antagonistas & inibidores
Náusea/tratamento farmacológico
Náusea/enzimologia
Vômito Precoce/tratamento farmacológico
Vômito Precoce/enzimologia
[Mh] Termos MeSH secundário: Doença Aguda
Amidoidrolases/metabolismo
Animais
Córtex Cerebral/efeitos dos fármacos
Modelos Animais de Doenças
Endocanabinoides/farmacologia
Inibidores Enzimáticos/farmacologia
Masculino
Monoacilglicerol Lipases/metabolismo
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Endocannabinoids); 0 (Enzyme Inhibitors); EC 3.1.1.23 (Monoacylglycerol Lipases); EC 3.5.- (Amidohydrolases); EC 3.5.1.- (fatty-acid amide hydrolase)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160407
[St] Status:MEDLINE
[do] DOI:10.1007/s00213-016-4277-y


  4 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26974857
[Au] Autor:Limebeer CL; Rock EM; Puvanenthirarajah N; Niphakis MJ; Cravatt BF; Parker LA
[Ad] Endereço:Department of Psychology, University of Guelph.
[Ti] Título:Elevation of 2-AG by monoacylglycerol lipase inhibition in the visceral insular cortex interferes with anticipatory nausea in a rat model.
[So] Source:Behav Neurosci;130(2):261-6, 2016 Apr.
[Is] ISSN:1939-0084
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anticipatory nausea (AN) is a conditioned nausea reaction experienced by chemotherapy patients upon returning to the clinic. Currently, there are no specific treatments for this phenomenon, with the classic antiemetic treatments (e.g., ondansetron) providing no relief. The rat model of AN, contextually elicited conditioned gaping reactions in rats, provides a tool for assessing potential treatments for this difficult to treat disorder. Systemically administered drugs which elevate the endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), by interfering with their respective degrading enzymes, fatty acid amide hydrolase (FAAH) and monoacyl glycerol lipase (MAGL) interfere with AN in the rat model. We have shown that MAGL inhibition within the visceral insular cortex (VIC) interferes with acute nausea in the gaping model (Sticht et al., 2015). Here we report that bilateral infusion of the MAGL inhibitor, MJN110 (but neither the FAAH inhibitor, PF3845, nor ondansetron) into the VIC suppressed contextually elicited conditioned gaping, and this effect was reversed by coadministration of the CB1 antagonist, AM251. These findings suggest that 2-AG within the VIC plays a critical role in the regulation of both acute nausea and AN. Because there are currently no specific therapeutics for chemotherapy patients that develop anticipatory nausea, MAGL inhibition by MJN110 may be a candidate treatment. (PsycINFO Database Record
[Mh] Termos MeSH primário: Ácidos Araquidônicos/metabolismo
Córtex Cerebral/efeitos dos fármacos
Endocanabinoides/metabolismo
Glicerídeos/metabolismo
Monoacilglicerol Lipases/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amidoidrolases
Animais
Ácidos Araquidônicos/uso terapêutico
Endocanabinoides/uso terapêutico
Glicerídeos/uso terapêutico
Cloreto de Lítio/farmacologia
Modelos Animais
Monoacilglicerol Lipases/metabolismo
Náusea
Alcamidas Poli-Insaturadas
Ratos
Ratos Sprague-Dawley
Serotonina
Vômito Precoce/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Arachidonic Acids); 0 (Endocannabinoids); 0 (Glycerides); 0 (Polyunsaturated Alkamides); 333DO1RDJY (Serotonin); 8D239QDW64 (glyceryl 2-arachidonate); EC 3.1.1.23 (Monoacylglycerol Lipases); EC 3.5.- (Amidohydrolases); EC 3.5.1.- (fatty-acid amide hydrolase); G4962QA067 (Lithium Chloride); UR5G69TJKH (anandamide)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160315
[St] Status:MEDLINE
[do] DOI:10.1037/bne0000132


  5 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25112561
[Au] Autor:Chan A; Kim HK; Hsieh RK; Yu S; de Lima Lopes G; Su WC; Baños A; Bhatia S; Burke TA; Keefe DM
[Ad] Endereço:National University of Singapore, Singapore, Singapore, phaac@nus.edu.sg.
[Ti] Título:Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis.
[So] Source:Support Care Cancer;23(1):283-91, 2015 Jan.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Some patients experience nausea and/or vomiting (NV) before receipt of chemotherapy. Our objective was to evaluate the impact of prior chemotherapy-induced NV (CINV) on the incidence of anticipatory NV in later cycles. METHODS: This multicenter, prospective non-interventional study enrolled chemotherapy-naïve adults scheduled to receive highly or moderately emetogenic chemotherapy (HEC/MEC) for cancer in six Asia Pacific countries, excluding those with emesis within 24 h before cycle 1 chemotherapy. On day 1 before chemotherapy, patients answered four questions regarding emesis in the past 24 h, nausea, expectation of post-chemotherapy nausea, and anxiety in the past 24 h, the latter three scored from 0-10 (none-maximum). Multivariate logistic regression was used to assess the impact of prior CINV on anticipatory NV in cycles 2 and 3. RESULTS: Five hundred ninety-eight patients (59% female) were evaluable in cycle 2 (49% HEC, 51% MEC). The incidence of anticipatory emesis was low before cycles 2 and 3 (1.5-2.3%). The incidence of clinically significant anticipatory nausea (score of ≥3) was 4.8, 7.9, and 8.3% before cycles 1, 2, and 3, respectively, with adjusted odds ratio (OR), 3.95 (95% confidence interval (CI), 2.23-7.00; p < 0.001) for patients with clinically significant nausea in prior cycles, compared with none. The adjusted ORs for other anticipatory NV endpoints ranged from 4.54-4.74 for patients with prior CINV. The occurrence of clinically significant anxiety in the prior cycle also resulted in a significantly increased likelihood of anticipatory nausea. CONCLUSIONS: These findings highlight the importance of preventing CINV in cycle 1 to reduce anticipatory NV in subsequent cycles.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Náusea/epidemiologia
Vômito Precoce/epidemiologia
Vômito/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Antieméticos/uso terapêutico
Antineoplásicos/uso terapêutico
Ásia/epidemiologia
Feminino
Seres Humanos
Incidência
Modelos Logísticos
Masculino
Meia-Idade
Náusea/induzido quimicamente
Náusea/tratamento farmacológico
Neoplasias/tratamento farmacológico
Estudos Prospectivos
Inquéritos e Questionários
Vômito/induzido quimicamente
Vômito/tratamento farmacológico
Vômito Precoce/tratamento farmacológico
Vômito Precoce/prevenção & controle
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiemetics); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140813
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-014-2375-0


  6 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24157982
[Au] Autor:Kamen C; Tejani MA; Chandwani K; Janelsins M; Peoples AR; Roscoe JA; Morrow GR
[Ad] Endereço:University of Rochester Medical Center, Behavioral Medicine Unit, 265 Crittenden Blvd, Box 420658, Rochester, NY 14642, United States. Electronic address: Charles_kamen@urmc.rochester.edu.
[Ti] Título:Anticipatory nausea and vomiting due to chemotherapy.
[So] Source:Eur J Pharmacol;722:172-9, 2014 Jan 05.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:As a specific variation of chemotherapy-induced nausea and vomiting, anticipatory nausea and vomiting (ANV) appears particularly linked to psychological processes. The three predominant factors related to ANV are classical conditioning; demographic and treatment-related factors; and anxiety or negative expectancies. Laboratory models have provided some support for these underlying mechanisms for ANV. ANV may be treated with medical or pharmacological interventions, including benzodiazepines and other psychotropic medications. However, behavioral treatments, including systematic desensitization, remain first line options for addressing ANV. Some complementary treatment approaches have shown promise in reducing ANV symptoms. Additional research into these approaches is needed. This review will address the underlying models of ANV and provide a discussion of these various treatment options.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/psicologia
Náusea/induzido quimicamente
Náusea/psicologia
Vômito Precoce/induzido quimicamente
Vômito Precoce/psicologia
[Mh] Termos MeSH secundário: Animais
Terapias Complementares
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/tratamento farmacológico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/terapia
Seres Humanos
Náusea/tratamento farmacológico
Náusea/terapia
Vômito Precoce/tratamento farmacológico
Vômito Precoce/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1409
[Cu] Atualização por classe:161025
[Lr] Data última revisão:
161025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131026
[St] Status:MEDLINE


  7 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23782493
[Au] Autor:Geiger F; Wolfgram L
[Ad] Endereço:Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Schwanenweg 20, Kiel 24105, Germany. f.geiger@uksh.de
[Ti] Título:Overshadowing as prevention of anticipatory nausea and vomiting in pediatric cancer patients: study protocol for a randomized controlled trial.
[So] Source:Trials;14:103, 2013 Apr 20.
[Is] ISSN:1745-6215
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Emesis and nausea are side effects induced by chemotherapy. These effects lead to enormous stress and strain on cancer patients. Further consequences may include restrictions in quality of life, cachexia or therapy avoidance. Evidence suggests that cancer patients develop the side effects of nausea and vomiting in anticipation of chemotherapy. Contextual cues such as smell, sounds or even the sight of the clinic may evoke anticipatory nausea and vomiting prior to infusion. Anticipatory nausea and vomiting are problems that cannot be solved by administration of antiemetica alone.The purpose of the proposed randomized placebo-controlled trial is to use an overshadowing technique to prevent anticipatory nausea and vomiting and to decrease the intensity and duration of post-treatment nausea and vomiting. Furthermore, the effect on anxiety, adherence and quality of life will be evaluated. METHODS/DESIGN: Fifty-two pediatric cancer patients will be evenly assigned to two groups: an experimental group and a control group. The participants, hospital staff and data analysts will be kept blinded towards group allocation. The experimental group will receive during three chemotherapy cycles a salient piece of candy prior to every infusion, whereas the control group will receive flavorless placebo tablets. DISCUSSION: If an effectiveness of the overshadowing technique is proven, implementation of this treatment into the hospitals' daily routine will follow. The use of this efficient and economic procedure should aid a reduced need for antiemetics. TRIAL REGISTRATION: Current Controlled Trials ISRCTN30242271/
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Doces
Condicionamento Clássico
Sinais (Psicologia)
Aprendizagem por Discriminação
Náusea/prevenção & controle
Projetos de Pesquisa
Vômito Precoce/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Comportamento do Adolescente
Fatores Etários
Antieméticos/uso terapêutico
Ansiedade/etiologia
Ansiedade/prevenção & controle
Ansiedade/psicologia
Criança
Comportamento Infantil
Pré-Escolar
Protocolos Clínicos
Alemanha
Seres Humanos
Adesão à Medicação
Náusea/etiologia
Náusea/psicologia
Qualidade de Vida
Fatores de Tempo
Resultado do Tratamento
Vômito Precoce/etiologia
Vômito Precoce/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antiemetics); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1310
[Cu] Atualização por classe:150424
[Lr] Data última revisão:
150424
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130621
[St] Status:MEDLINE
[do] DOI:10.1186/1745-6215-14-103


  8 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23064080
[Au] Autor:Chan MY; Cross-Mellor SK; Kavaliers M; Ossenkopp KP
[Ad] Endereço:Department of Psychology, University of Western Ontario, London, Ontario, Canada N6A 5C2. melchan@psych.ubc.ca
[Ti] Título:Impairment of lithium chloride-induced conditioned gaping responses (anticipatory nausea) following immune system stimulation with lipopolysaccharide (LPS) occurs in both LPS tolerant and LPS non-tolerant rats.
[So] Source:Brain Behav Immun;27(1):123-32, 2013 Jan.
[Is] ISSN:1090-2139
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Anticipatory nausea is a classically conditioned response to a context that has been previously paired with toxin-induced nausea and/or vomiting. When injected with a nausea-inducing drug, such as lithium chloride (LiCl), rats will show a distinctive conditioned gaping response that has been suggested to be an index of nausea. Previous studies have found that immune system activation with an endotoxin, such as lipopolysaccharide (LPS), attenuates LiCl-induced conditioned gaping in rats. The present study examined the acquisition of LiCl-induced conditioned gaping in rats that were either LPS tolerant or LPS non-tolerant, as little is known about the effects of endotoxin tolerance on learning and memory. Male Long-Evan rats were given four systemic injections of LPS (200 µg/kg) or isotonic saline (NaCl) to induce LPS tolerance, indexed with 24 h changes in body weight following treatment. The animals were then given 4 acquisition trials in a LiCl-induced conditioned gaping paradigm. On conditioning days animals were treated with LPS (200 µg/kg) or saline followed 90 min later by injection of LiCl (127 mg/kg) or saline and then placed in a distinctive context for 30 min and their behavior video-recorded. On a drug free test day all animals were again placed in the distinctive context for 10 min and behavior was video-recorded. Gaping responses were scored for all acquisition days and the test day. Spleen and body weights were also obtained for all rats at the end of the experiment. Gaping responses were attenuated in rats treated with LPS in both the LPS tolerant and LPS non-tolerant groups. There were significant negative correlations between spleen weight as well as spleen/body weight ratios, and levels of conditioned gaping responses in LiCl treated rats, but not control rats. These results show that LPS interferes with learning/memory in the anticipatory nausea paradigm in rats that are both LPS tolerant and LPS non-tolerant.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Condicionamento Clássico
Endotoxinas/farmacologia
Lipopolissacarídeos/farmacologia
Cloreto de Lítio/farmacologia
Náusea
[Mh] Termos MeSH secundário: Animais
Comportamento Animal/efeitos dos fármacos
Comportamento Animal/fisiologia
Condicionamento Clássico/efeitos dos fármacos
Condicionamento Clássico/fisiologia
Tolerância a Medicamentos/fisiologia
Masculino
Memória/efeitos dos fármacos
Memória/fisiologia
Tamanho do Órgão
Ratos
Ratos Long-Evans
Baço/efeitos dos fármacos
Baço/patologia
Vômito Precoce/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Endotoxins); 0 (Lipopolysaccharides); G4962QA067 (Lithium Chloride)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121016
[St] Status:MEDLINE


  9 / 225 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21818642
[Au] Autor:Ryan JL; Heckler CE; Roscoe JA; Dakhil SR; Kirshner J; Flynn PJ; Hickok JT; Morrow GR
[Ad] Endereço:Departments of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY 14642, USA. julie_ryan@urmc.rochester.edu
[Ti] Título:Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.
[So] Source:Support Care Cancer;20(7):1479-89, 2012 Jul.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Despite the widespread use of antiemetics, nausea continues to be reported by over 70% of patients receiving chemotherapy. METHODS: In this double blind, multicenter trial, we randomly assigned 744 cancer patients to four arms: 1) placebo, 2) 0.5 g ginger, 3) 1.0 g ginger, or 4) 1.5 g ginger. Nausea occurrence and severity were assessed at a baseline cycle and the two following cycles during which patients were taking their assigned study medication. All patients received a 5-HT(3) receptor antagonist antiemetic on Day 1 of all cycles. Patients took three capsules of ginger (250 mg) or placebo twice daily for 6 days starting 3 days before the first day of chemotherapy. Patients reported the severity of nausea on a 7-point rating scale ("1" = "Not at all Nauseated" and "7" = "Extremely Nauseated") for Days 1-4 of each cycle. The primary outcomes were to determine the dose and efficacy of ginger at reducing the severity of chemotherapy-induced nausea on Day 1 of chemotherapy. RESULTS: A total of 576 patients were included in final analysis (91% female, mean age = 53). Mixed model analyses demonstrated that all doses of ginger significantly reduced acute nausea severity compared to placebo on Day 1 of chemotherapy (p = 0.003). The largest reduction in nausea intensity occurred with 0.5 g and 1.0 g of ginger (p = 0.017 and p = 0.036, respectively). Anticipatory nausea was a key factor in acute chemotherapy-induced nausea (p < 0.0001). CONCLUSIONS: Ginger supplementation at a daily dose of 0.5 g-1.0 g significantly aids in reduction of the severity of acute chemotherapy-induced nausea in adult cancer patients.
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Gengibre/química
Náusea/prevenção & controle
Fitoterapia
Vômito/prevenção & controle
[Mh] Termos MeSH secundário: Antieméticos/administração & dosagem
Antieméticos/isolamento & purificação
Antineoplásicos/efeitos adversos
Antineoplásicos/uso terapêutico
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Náusea/induzido quimicamente
Neoplasias/tratamento farmacológico
Antagonistas do Receptor 5-HT3 de Serotonina/uso terapêutico
Índice de Gravidade de Doença
Resultado do Tratamento
Vômito/induzido quimicamente
Vômito Precoce/prevenção & controle
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antiemetics); 0 (Antineoplastic Agents); 0 (Serotonin 5-HT3 Receptor Antagonists)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110806
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-011-1236-3


  10 / 225 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20811914
[Au] Autor:Pirri C; Katris P; Trotter J; Bayliss E; Bennett R; Drummond P
[Ad] Endereço:Faculty of Health Sciences (Psychology), Murdoch University, South Street, Murdoch, WA 6150, Australia. cpirri@gmail.com.
[Ti] Título:Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study.
[So] Source:Support Care Cancer;19(10):1549-63, 2011 Oct.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Despite significant advances in antiemetic management, almost 50% of cancer patients still experience nausea and vomiting during treatment. The goal of antiemetic therapy is complete prevention of treatment-induced nausea and/or vomiting (TINV); however, realisation of this goal remains elusive, thus supplementary strategies identifying patients at high risk must be employed in the interim. Consequently, we examined TINV incidence and its risk factors, including patient, clinical and pretreatment quality of life (QOL)/psychological factors. METHODS: Two hundred newly diagnosed cancer patients beginning combined treatment participated in this prospective, longitudinal, observational study. QOL (including TINV), psychological adjustment, and patient/clinical characteristics were examined at pretreatment, on-treatment (8 weeks ± 1 week) and post-treatment. RESULTS: Overall, 62% of patients experienced TINV, with TIN incidence (60%) doubling that of TIV (27%). Eight independent risk factors predicted 73% of TIN incidence: high premorbid/anticipatory NV, moderately/highly emetogenic chemotherapy (M/HEC), longer treatment (>3 months), female gender, surgery prior to adjuvant chemotherapy ± radiotherapy, private health insurance and low emotional functioning (pretreatment). Six independent risk factors predicted 77% of TIV incidence: premorbid/anticipatory vomiting, M/HEC, female gender, cancer resection and low role functioning (pretreatment). CONCLUSIONS: TINV still represents a very major concern for patients. Several pretreatment risk factors for the development of TIN and TIV, respectively, were identified. Patients about to undergo cancer treatment, particularly combined treatment involving emetogenic chemotherapy and surgery, should be screened for these factors with a view to modifying standard pretreatment/maintenance antiemetic therapy. Furthermore, and consistent with recent research, it is recommended that more comprehensive interventions combining antiemetics with other effective pharmacological (e.g. anxiolytics) and non-pharmacological approaches (e.g. acupuncture, relaxation techniques) be considered by clinicians in attempts to improve control of TIN and TIV (and overall QOL) for their patients. In this way, optimal holistic care will be ensured for cancer patients by clinicians providing conventional oncology treatment.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Náusea/induzido quimicamente
Neoplasias/tratamento farmacológico
Qualidade de Vida
Vômito/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/uso terapêutico
Austrália
Feminino
Seres Humanos
Incidência
Estudos Longitudinais
Masculino
Meia-Idade
Náusea/epidemiologia
Neoplasias/terapia
Estudos Prospectivos
Fatores de Risco
Fatores Sexuais
Fatores de Tempo
Vômito/epidemiologia
Vômito Precoce/psicologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100903
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-010-0982-y



página 1 de 23 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde